The Role and Therapeutic Targeting of CCR5 in Breast Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• C-C chemokine receptor 5 (CCR5) is a G-protein-coupled receptor crucial for HIV entry into immune cells.
• CCR5 is also found on breast cancer epithelial cells, where it drives aberrant survival signaling and chemoattractant tropism.
• Its presence on cancer cells but not normal epithelium makes CCR5 a potential therapeutic target.

Purpose of the Study:

• To review the role of CCR5 in breast cancer.
• To discuss the therapeutic potential of CCR5 inhibitors (CCR5i) in cancer treatment.
• To highlight emerging clinical findings and combination therapy strategies involving CCR5i.

Main Methods:

• Literature review of preclinical and early clinical studies on CCR5 and CCR5 inhibitors in breast cancer.
• Analysis of CCR5 expression, function, and therapeutic targeting in breast cancer models.
• Evaluation of clinical trial data for CCR5 inhibitors, including monotherapy and combination approaches.

Main Results:

• CCR5 inhibitors (small molecules and antibodies) demonstrate anti-tumor and anti-metastatic effects in preclinical studies.
• Early clinical studies indicate that CCR5 inhibitors yield promising results, impacting both the tumor and the anti-tumor immune response.
• Combination therapies involving CCR5 inhibitors and checkpoint inhibitors are being explored in current clinical trials.

Conclusions:

• CCR5 represents a viable therapeutic target for breast cancer due to its specific expression on cancer cells.
• CCR5 inhibitors have demonstrated significant potential in preclinical and early clinical settings for breast cancer treatment.
• Combination strategies, particularly with checkpoint inhibitors, are a key focus for advancing CCR5-targeted therapies in oncology.